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Abstract 
Background: The G protein-coupled receptor, adenosine A2A, signals through the stimulatory 
G protein, Gs in platelets leading to activation of adenylyl cyclase and elevation of cAMP and 
inhibition of platelet activation. 
Objective: To investigate the effect of A2A receptor activation on signalling by the collagen 
receptor glycoprotein (GP) VI in platelets. 
Methods: Washed human platelets were stimulated by collagen or the GPVI-specific agonist 
collagen-related-peptide (CRP) in the presence of the adenosine receptor agonist, 5'-N-
ethylcarboxamidoadenosine (NECA) or the adenylyl cyclase activator, forskolin and analysed 
for aggregation, ATP secretion, protein phosphorylation, spreading, Ca2+ mobilisation, GPVI 
receptor clustering, cAMP, TxB2 and P-selectin exposure. 
Results: NECA, a bioactive adenosine analogue, partially inhibits aggregation and secretion 
to collagen or CRP in the absence or presence of the P2Y12 receptor antagonist, cangrelor and 
the cyclooxygenase inhibitor, indomethacin.  The inhibitory effect in the presence of the three 
inhibitors is largely overcome at higher concentrations of collagen but not CRP. Neither NECA 
nor forskolin altered clustering of GPVI, elevation of Ca2+ or spreading of platelets on a 
collagen surface. Further, neither NECA nor forskolin, altered collagen induced tyrosine 
phosphorylation of Syk, LAT nor PLCγ2. However, NECA and forskolin inhibited platelet 
activation by the thromboxane A2 (TxA2) mimetic, U46619, but not the combination of ADP 
and collagen.
Conclusion: NECA and forskolin have no effect on the proximal signalling events by collagen. 
They inhibit platelet activation in a response specific manner in part through inhibition of the 
feedback action of thromboxane A2. 
Key words: adenosine, cAMP, collagen, glycoprotein VI (GPVI) receptor, platelets
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Summary Table 
Introduction
Platelets are small anucleate cytoplasmic discs derived from megakaryocytes in the bone 
marrow that circulate in the blood. They play a vital role in the control of haemostasis and 
thrombus formation as well as in supporting inflammation, immunity, angiogenesis and 
vascular integrity1. Platelets are exposed to prostacyclin and nitric oxide at the endothelial 
surface which leads to elevation of cAMP and cGMP, respectively2. This is the most potent 
endogenous mechanism of platelet inhibition3. cAMP and cGMP activate the cyclic nucleotide-
dependent protein kinases, PKA and PKG respectively, leading to phosphorylation of a wide 
variety of substrate proteins4. The consequences of phosphorylation include inhibition of Ca2+ 
release from intracellular stores5, modulation of cytoskeletal actin dynamics via vasodilator-
stimulated phosphoprotein (VASP), LIM and SH3 domain protein (LASP), heat shock protein 
(HSP) 27, filamin-A and caldesmon6-8, and inhibition of heterotrimeric and small G proteins. 
This leads to inhibition of integrin activation, secretion and adhesion9. 
What is known about this topic?
 Adenosine stimulates cAMP formation leading to inhibition of platelet activation 
by collagen.
 There are contrasting reports on whether the proximal signalling events induced by 
collagen are altered in the presence of cAMP elevation.
What this paper adds? 
 Adenosine has no effect on the proximal events in the GPVI signalling cascade up to 
intracellular Ca2+ but inhibits the feedback action of downstream signals including 
thromboxane A2. 
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Collagen binds to the immunoglobulin receptor glycoprotein (GP) VI which is its major 
signalling receptor in platelets, and to integrin α2β1 which supports platelet adhesion10. GPVI 
forms a complex in the membrane with the FcR-chain which contains an immunoreceptor 
tyrosine-based activation motif (ITAM) defined by the presence of two YxxL groups (single 
amino acid code) separated by 12 amino acids11.  Collagen binds selectively to dimeric GPVI12 
and induces phosphorylation of the conserved tyrosine residues in the ITAM through the action 
of Src family kinases.  This leads to binding of the tyrosine kinase Syk through its tandem SH2 
domains and initiation of a downstream signalling pathway that culminates in activation of 
PLC210. Collagen activates platelets at sites of vascular lesions and so it is important to 
understand how collagen is able to do this in the presence of elevated levels of cyclic 
nucleotides.
Adenosine is an endogenous nucleotide that inhibits platelet activation by ADP and collagen 
through A2A and A2B receptors. Both receptors activate the heterotrimeric G protein subunit, 
Gs, leading to elevation of cAMP13-15. Adenosine has been reported to inhibit platelet 
aggregation, ATP secretion, P-selectin cell surface expression and adhesion to a collagen 
surface14 and to inhibit thrombus formation in vivo14. The inhibitory action of adenosine may 
contribute to the clinical efficacy of the P2Y12 receptor antagonist, ticagrelor, which inhibits 
uptake of adenosine into platelets16. 
There are also reports that cAMP does not inhibit platelet activation by collagen. For example, 
prostacyclin which increases cAMP levels, has been reported to inhibit thrombin but not 
collagen induced tyrosine phosphorylation and signalling17-19. In addition collagen induced 
shape change, which is mediated by Ca2+ mobilisation, is insensitive to cAMP 20. On the other 
hand, Loyau et al21 reported that elevation of cAMP inhibits binding of a monoclonal antibody 
(mAb), 9E18, that binds selectively to dimeric GPVI, and Takayama et al22 reported that cAMP 
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promotes endocytosis of GPVI. Both actions should result in inhibition of platelet activation 
by collagen. 
In view of these contrasting reports, the aim of the present study was to investigate the effect 
of adenosine and forskolin which is a more powerful stimulus of adenylyl cyclase, on platelet 
activation by collagen. We report that adenosine and forskolin inhibit platelet aggregation by 
low concentrations but not high concentrations of collagen downstream of the proximal 
signalling events including elevation of intracellular Ca2+.
Methods 
Materials
Horm collagen was obtained from Takeda (High Wycombe, UK). NECA (5'-N-
ethylcarboxamidoadenosine) was purchased from Tocris Bioscience (Bristol, UK). Cangrelor 
was purchased from Medicines Company. U46619 was obtained from Cayman Chemical. 
Chronolume and ATP were from Chrono-log Corporation (Manchester, UK). Horseradish 
peroxidase (HRP)-conjugated secondary antibodies and Enhanced Chemiluminescence (ECL) 
substrate were obtained from Amersham Biosciences (GE Healthcare, Bucks, UK). Oregon 
green 488 BAPTA-1-AM was purchased from Invitrogen (Invitrogen, ThermoFisher 
Scientific, Paisley, UK). Other reagents were obtained from Sigma.
Antibodies: PLCγ2 p1217, PLCγ2 p759, Syk p525/526, Syk p323, Syk p352, LAT p132 and 
LAT p171 were from Cell Signalling Technology (Danvers, Massachusetts, United States). 
LAT p200 mAb was obtained from Abcam (Cambridge, UK). Mouse anti-human anti-
phosphotyrosine (clone 4G10) mAb was from Millipore UK Ltd (Watford, UK). Alexa Fluor 
488 phalloidin and Alexa Fluor 647 were purchased from Invitrogen (Invitrogen, 
ThermoFisher Scientific, Paisley, UK). 1G5-Fab recognises monomeric and dimeric GPVI was 
raised as described23.
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Preparation of human washed platelets
Blood was collected from healthy and consenting volunteers by venipuncture in accordance 
with the Declaration of Helsinki (local ethical review no: ERN_11-0175). Trisodium citrate [1 
part 3.8% (w/v) stock: 9 parts blood] was used as the anticoagulant. Washed platelets were 
prepared by centrifugation in the presence of prostacyclin (2.8 μM) followed by resuspension 
in Tyrodes-HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3 
20 mM HEPES, 1 mM MgCl2, 5 mM glucose, pH 7.3) as previously described24. Platelet count 
was measured using a Coulter counter and the suspension was diluted to the required 
concentration in Tyrodes-HEPES buffer. Platelets were then left for 30 min. For aggregation 
and ATP secretion measurements platelets were used at 2x108/ml; for western blotting at 
5x108/ml and for spreading at 2x107/ml. 
Aggregometry and luminescence measurement of ATP secretion
Aggregation was monitored using a Chrono-Log optical aggregometer (Labmedics, 
Manchester, UK) at 37oC with constant stirring at 1200 rpm. Secretion of ATP was measured 
using luciferin-luciferase Chrono-lume reagent (Chrono-Log). NECA (100 μM), indomethacin 
(10 μM), cangrelor (10 μM), forskolin (10 μM), ADP (10 μM) or vehicle were added 60-120 
sec before collagen, CRP or U46619.  The platelets were left for 5 min before addition of ATP 
(2 nM) for calibration of ATP secretion. 
Platelet lysis and protein phosphorylation 
Whole cell lysates were prepared from 400 μl sample of stirred platelet suspensions. 
Eptifibatide (9 μM) was added to prevent aggregation. The reaction was terminated by the 
addition of 5x SDS sample buffer (reducing conditions) to the platelets. The samples were heat 
denatured at 100oC for 5 min and spun at 15000 g for 10 min.  The whole cell lysate was 
electrophoresed on 4-12% BisTris Plus acrylamide Bolt gels (Invitrogen, Paisley, UK) and 
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transferred onto PVDF membranes using a Trans-blot Transfer Imaging system (Bio-Rad, 
Hertfordshire, UK). Each gel included at least one lane of 10 μl of Color Prestained Protein 
Standard (11–245 kDa; NEB, Ipswich, Massachusetts, United States). Membranes were 
blocked in 4% (w/v) BSA dissolved in TBST and 0.1% (w/v) sodium azide for a minimum of 
1 h at room temperature and incubated overnight at 4oC with anti-phosphotyrosine (clone 
4G10; 1:1,000), PLCγ2 (Tyr 1217; 1:250, Tyr 759; 1:1,000), Syk (Tyr 525/526; 1:500, Tyr 
352; 1:1,000, Tyr 323; 1:1,000)  and LAT (Tyr 200; 1:500, Tyr 171; 1:1,000, Tyr 132; 1:500) 
primary antibodies. Membranes were imaged using the Licor Odyssey system. Quantification 
of band intensities was performed using Image Studio Lite v5.2 where background correction 
was applied. 
Human platelet spreading 
Glass coverslips were coated with collagen (10 μg/ml) in manufacturer-supplied diluent 
overnight at 4oC. The coverslips were blocked with 5 mg/ml BSA in PBS (heat denatured, 
filter-sterilised) for 1 h at room temperature, then washed with PBS. Washed platelets were 
incubated on collagen for 30 min at 37oC and NECA and forskolin were added and left for an 
additional 30 min. Pre-incubation experiments were conducted where NECA and forskolin 
were incubated with platelets for 30 min and followed by 30 min spreading.  Following 
spreading the coverslips were washed in PBS and adherent platelets were fixed in 4% (w/v) 
formalin for 10 min at room temperature, permeabilized with 0.1% (v/v) Triton X-100 (in PBS) 
and stained with phalloidin-Alexa Fluor 488.  The coverslips were mounted and imaged with 
a Zeiss Observer 7 Epifluorescent microscope using a 63x 1.4NA oil immersion lens. Images 
were acquired using Zen Pro v2.3 and processed using FIJI v1.51. Using the open-source 
KNIME software25 platelet segmentation was performed and platelet count and surface area 
were analysed. An ilastik26 pixel classifier was used to produce a binary segmentation. To 
separate touching platelets the centre of individual platelets were manually selected using 
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KNIME. These centre coordinates were then used as seeds for a watershed transform to 
produce the final segmentation result. Objects smaller than 1 μm2 were discarded and platelet 
statistics including platelet area were calculated.
Single cell Ca2+ measurements
For Ca2+ measurements, washed platelets were incubated for 45 min at 37°C with Oregon green 
488 BAPTA-1-AM (1 μM) in Tyrodes-HEPES buffer and centrifuged at 1000 g for 10 min 
with prostacyclin (2.8 μM) and resuspended in Tyrodes-HEPES buffer. Glass bottomed MatTek 
dishes (No. 1.5 (0.17 mm) coverslips) (MatTek, Ashland, MA, USA) were prepared as 
previously described27. Washed platelets were prepared and left to rest for 30 min. The platelets 
were diluted to 2x107/ml and prior to exposure to an immobilized collagen surface were 
incubated with forskolin or indomethacin and cangrelor or all three inhibitors for 2 min. Real-
time platelet Ca2+ flux was monitored using a Zeiss Observer 7 Epifluorescent microscope 
using a 63x 1.4NA oil immersion lens, Colibri 7 LED light source, Zeiss Filter set 38 for 
GFP/FITC, and Hammamatsu ORCA Flash 4 LT sCMOS camera where images were taken 
every 2 sec for 100 cycles. Images were acquired using Zen Pro v2.3 and processed using FIJI 
v1.51. The number of peaks and peak fluorescence intensity were analyzed in 75 platelets for 
each condition. Ca2+ spikes were identified where an increase in fluorescence intensity greater 
than 100 (a.u.) above baseline was observed. Where prolonged Ca2+ signals were detected, 
peaks were subdivided into multiple peaks when a clear change in direction of the trace was 
observed. 
Total internal reflection microscopy (TIRFM)/direct STocastic Optical Reconstruction 
Microscopy (dSTORM) 
Glass bottomed MatTek dishes (No. 1.5 (0.17 mm) coverslips) were coated with collagen (10 
μg/ml) as previously described27. 1G5 Fab (pan-GPVI)-labelled (2 μg/ml) washed platelets 
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(2x107/ml) were allowed to adhere and spread for 30 min to the collagen-coated MatTek dishes. 
NECA (100 μM) and forskolin (10 μM) were added and platelets were spread for an additional 
30 min. Adherent platelets were fixed in 4% (w/v) formalin for 10 min at room temperature, 
permeabilized with 0.1% (v/v) Triton X-100 (in PBS), blocked for 30 min in 2% (v/v) goat 
serum and 1% BSA (w/v) and then stained with phalloidin-Alexa Fluor 488 and Alexa Fluor 
647-conjugated IgG secondary antibodies (diluted 1:300 in block buffer). Adhesion of 1G5 
Fab-labelled washed platelets (2x107/ml) to immobilised collagenous substrate was imaged in 
TIRF using a fully motorised Nikon TIRF combine mounted on a NIKON N-STORM 
microscope on a Ti-E stand equipped with a Nikon 100x 1.49 NA TIRF oil objective, Perfect 
Focus System, Agilent MLC400 laser bed with 405 nm (50 mW*), 488 nm (80 mW*), 561 nm 
(80 mW*) and 640 nm (125 mW*) solid-state lasers and Andor iXon Ultra EM-CCD camera 
as previously described27. Samples were maintained in an OKO environmental chamber at 
28oC for maximum system stability during imaging. All dSTORM experiments were 
performed in TIRF mode on a NIKON N-STORM microscope as described previously27. 
During dSTORM acquisition, the sample was continuously illuminated at 640 nm for 20,000 
frames (40 x 40 μm, 9.2 ms exposure time) and the 405 nm laser was used for back pumping. 
Samples were imaged in switching buffer (0.5 mg/ml glucose oxidase, 40 µg/ml catalase, 10% 
(w/v) glucose and 100 mM β-mercaptoethylamine in PBS, pH 7.4) to induce Alexa 647 
blinking28. The 20,000 frames were captured with Nikon NIS ELEMENTS v4.5 and 
reconstructed in ThunderSTORM imageJ plugin29 where approximate molecule positions are 
determined. The settings used were Gaussian PSF modelling and maximum likelihood fitting. 
Further post processing analysis include: lateral drift correction, local density filtering where 
the distance ratio was 50 and minimum number of neighbors was 5 and merging of reappearing 
localizations. All detections in sequential within 20 nm were merged. Gaussian rendering was 
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implemented for visualization.  Points in the reconstructed images represent individually 
identified fluorescent blinking events, which are referred to as detections. 
Cluster analysis
After localising detections, density-based spatial clustering of applications with 
noise (DBSCAN) 30 was used to group detections into clusters and segment clusters of arbitrary 
shape such as on collagen fibres. For DBSCAN the radius of the local neighbourhood was set 
to 50 nm and the minimum number of directly reachable points was set to 10. Edge points were 
included in clusters. Cluster area was calculated by placing a circle with a radius of 50 nm over 
every detection in a cluster and calculating the union of these circles. This was estimated using 
a grid with a pixel size of 5 nm and image based dilation. Cluster density was defined as the 
number of detections within a cluster divided by the cluster area. This analysis was performed 
on whole fields of view using the open-source software KNIME25. DBSCAN was implemented 
within KNIME using the R package ‘dbscan’. 
Statistical analysis 
Each experiment was performed at least three times and r sults are shown as mean± SEM. Data 
were analysed using PRISM v7.04 (GraphPad, San Diego, CA.) and statistical analysis was by 
one-way ANOVA with a Bonferroni post-hoc test. Significance was set at p ≤ 0.05. 
Results 
The effect of NECA and inhibitors of feedback agonists on aggregation and secretion 
induced by collagen.
We investigated the effect of the A2A receptor agonist NECA31 (1, 10 and 100 μM) on platelet 
aggregation induced by low (2 μg/ml) and intermediate (10 μg/ml) concentrations of collagen 
(Supplementary Fig. 1). Both concentrations of collagen stimulated aggregation after a delay 
Page 10 of 33Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
11
of approximately 15 sec which reached approximately 95% of the maximal aggregation within 
2 min (Supplementary Fig. 1).  In the presence of NECA (1-100 μM), aggregation to a low 
concentration of collagen (2 μg/ml) was partially reduced and began to slowly return to the 
resting level. In contrast, NECA (1 μM) had no significant effect on the response to an 
intermediate concentration (10 μg/ml) of collagen whereas the maximal level of aggregation, 
but not the time course of response, was partially inhibited in the presence of NECA (10 and 
100 μM).  For these reasons, 100 μM NECA was chosen for further experiments. 
To investigate whether the mechanism of inhibition of the response to collagen by NECA was 
due to inhibition of the action of the secondary agonists, ADP and thromboxane A2 (TxA2), we 
first monitored aggregation and dense granule secretion (ATP release) in the presence of 
maximally effective concentrations of the P2Y12 receptor antagonist, cangrelor (10 μM) and 
the cyclooxygenase inhibitor indomethacin (10 μM). Both agents caused a partial inhibition of 
aggregation to collagen (10 μg/ml) which was similar to that induced by NECA (100 μM) but 
neither agent, separately or in combination with NECA had an effect on ATP secretion 
(Supplementary Fig. 2). A slightly greater level of inhibition of secretion was seen when 
cangrelor and indomethacin were used in combination, or when given with NECA, which did 
reach statistical significance (Fig. 1A). All three inhibitors blocked aggregation and secretion 
to a lower concentration of collagen (2 μg/ml) (Fig. 1B). The lack of an additional effect of 
NECA in the presence of cangrelor and indomethacin on aggregation and secretion to the 
higher concentration of collagen suggests that its inhibitory action is mediated predominantly 
by inhibition of the secondary feedback agonists.  
One explanation for the relatively weak effect of NECA on aggregation and secretion to 
collagen (10 μg/ml) is that it induces only a small increase in cAMP.  To address this, we used 
forskolin which induces powerful activation of adenylyl cyclase and therefore a much larger 
increase in cAMP (Supplementary Fig. 3A). Forskolin induced a similar effect to the 
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combination of cangrelor and indomethacin on collagen induced aggregation and ATP 
secretion (Fig. 1C). The combination of all three agents caused a slightly greater level of 
inhibition of aggregation and ATP secretion to that seen with NECA, cangrelor and 
indomethacin. 
To investigate whether the inhibitory effect of NECA was due to blockade of signalling by 
GPVI, we investigated the effect on aggregation and secretion induced by the GPVI-specific 
ligand, CRP. NECA or the combination of indomethacin and cangrelor has no significant effect 
on platelet aggregation to a high concentration of CRP (10 μg/ml), although the combination 
of indomethacin and cangrelor partially reduced secretion (Fig. 2A). Surprisingly however, 
both responses were markedly inhibited in the presence of all three inhibitors. In contrast, 
NECA alone and the combination of indomethacin and cangrelor blocked the response to a 
lower concentration of CRP (1 μg/ml) (Fig. 2B). This demonstrates that NECA is able to inhibit 
aggregation and secretion to CRP through a pathway that is unmasked by the absence of 
signalling by secondary agonists. 
We extended the studies on secretion to CRP (10 μg/ml) to measure the α-granule marker P-
selectin (Supplementary Fig 3B). CRP causes a significant increase in P-selectin exposure 
which is reduced in the presence of NECA and forskolin. 
Together these results show that NECA and forskolin block the response to threshold activation 
of GPVI in the presence of inhibition of the feedback agonists TxA2 and ADP. The inhibitory 
effect of NECA is largely overcome at higher concentrations of collagen but not CRP. 
The effect of NECA and forskolin on collagen induced protein tyrosine phosphorylation 
To investigate the mechanism underlying the inhibitory effect of the adenosine A2A receptor 
agonist NECA, we measured phosphorylation of key signalling proteins in the GPVI pathway 
by western blotting using phosphospecific antibodies.  We chose to focus on three proteins that 
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are phosphorylated at multiple sites and which play key roles in GPVI signalling, namely Syk, 
LAT and PLC2. We elected to use forskolin in the phosphorylation studies because it induces 
a greater increase in cAMP (Supplementary Fig. 3A). Phosphorylation was measured in the 
presence of maximally-effective concentrations of indomethacin and apyrase, inhibitors of the 
TxA2 and ADP feedback pathways, respectively. Incubation times used are in-line with 
previously published work18, 32. Strikingly, forskolin caused a minimal reduction in tyrosine 
phosphorylation of Syk at Y323 (docking), Y352 (docking) and Y525/526 (activation), LAT 
at Y132 (docking) and Y200 (docking), and PLC2 at Y759 (activation and docking) and 
Y1217 (activation) (Fig. 3ii). Similarly, NECA had no significant effect on phosphorylation of 
Syk, LAT and PLC2 at Y525/526, Y200 and Y1217, respectively (Supplementary Fig. 4).  
These results demonstrate that neither elevation of cAMP via stimulation of the adenosine A2A 
receptor or using the adenylyl cyclase activator, forskolin had a major effect on tyrosine kinase 
signalling downstream of platelet activation by collagen.
Adenosine and forskolin have no effect on platelet spreading or Ca2+ elevation induced 
by collagen 
The adhesion of platelets to a collagen surface leads to a rapid reorganization of the actin 
cytoskeleton resulting in formation of filopodia and eventually lamellipodia and stress fibres. 
Addition of NECA or forskolin to platelets that had been incubated a collagen-coated surface 
for 30 min had no significant effect on the degree of adhesion or platelet morphology as shown 
by measurement of surface area (Fig. 4A). A similar result was seen when NECA and forskolin 
were given prior to the onset of spreading (Fig. 4B) although the degree of platelet adhesion 
was markedly reduced. This suggests that adenosine and forskolin have an inhibitory effect 
prior to spreading but this is lost once platelet spreading and collagen signalling has begun. 
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To investigate if cAMP is inhibiting Ca2+ mobilization following collagen stimulation, we 
measured the frequency and fluorescence intensity of Ca2+ spikes in platelets spread on a 
collagen surface following treatment with forskolin, indomethacin and cangrelor. We elected 
to use forskolin in the single cell Ca2+ studies because it induces a greater increase in cAMP 
(Supplementary Fig. 3A). Forskolin either alone or in combination with indomethacin and 
cangrelor had no effect on the frequency of Ca2+ spikes or the fluorescence intensity of these 
spikes (Fig. 5). This suggests that Ca2+ elevation induced by collagen is not affected by 
elevation of cAMP. 
NECA and forskolin do n t change GPVI receptor clustering
To determine whether NECA or forskolin had an effect on endogenous GPVI clusters which 
form in platelets spreading on immobilized collagen, single molecule super resolution 
microscopy (dSTORM) was used. GPVI was labelled using a Fab fragment of the monoclonal 
antibody to pan-GPVI, 1G523. The platelets were allowed to adhere to collagen for 30 min 
before being treated with NECA or forskolin for a further 30 min to determine whether GPVI 
distribution was affected. Diffraction limited TIRF microscopy showed a characteristic GPVI 
distribution with enrichment of GPVI along collagen fibres, as has been shown previously27. 
dSTORM images show the localization of single molecule detections and the DBSCAN cluster 
plot shows clustering of the detections in the image where different clusters are represented by 
different colors. The largest clusters of GPVI can be seen along the collagen fibres. Results 
from the quantitative cluster analysis (Fig. 6Bi-iv) show that neither NECA nor forskolin 
altered GPVI clustering, with the number of clusters, number of detections per cluster and 
cluster area and density all similar to control values. 
NECA and forskolin inhibit TxA2 induced platelet aggregation
Page 14 of 33Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15
The effect of NECA and forskolin on TxB2 formation and platelet aggregation induced by the 
TxA2 mimetic, U46619, was investigated to determine the basis of loss of platelet activation.  
The thromboxane A2 (TP) receptor agonist U46619 caused ~60% maximal platelet 
aggregation. However, both NECA and forskolin caused a significant reduction in U46619 
induced platelet aggregation (Fig. 7A) with NECA reducing aggregation to ~10% and forskolin 
causing complete blockade. This suggests that cAMP is inhibiting thromboxane receptor 
signalling. In addition both NECA and forskolin also partially decreased TxB2 formation by 
collagen (Supplementary Fig. 3C) demonstrating that elevation of cAMP causes inhibition both 
upstream and downstream of TxA2. 
ADP does not cause aggregation in washed platelets due to desensitisation of the P2Y1 receptor 
which prevents synergy with the P2Y12 receptor. To investigate the effect of NECA on the 
response to P2Y12 receptor activation, we monitored platelet aggregation induced by a low 
concentration of collagen (2 μg/ml) in the absence and presence of ADP (Fig. 7C&D). On its 
own, ADP had no effect on aggregation. NECA inhibited the response to the low dose of 
collagen as described in Fig.1, but had no effect on the response to collagen in the presence of 
ADP (Fig. 7C&D). This demonstrates that NECA has a greater effect on the TxA2 arm of the 
feedback agonists. 
Discussion 
In the present study, we show that signalling via the adenosine A2A receptor and stimulation of 
adenylyl cyclase blocked platelet aggregation and ATP secretion induced by low 
concentrations of collagen but only had a partial effect against higher concentrations and 
present evidence that this is mediated in part by inhibition of TxA2 receptor signalling. 
Adenosine also blocked platelet aggregation and ATP secretion by a low concentration of the 
GPVI-selective agonist CRP, but only inhibited the response to a higher concentration in the 
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presence of the combination of a P2Y12 antagonist and cyclooxygenase inhibitor. Together 
these results show that platelet activation induced by high concentrations of collagen and the 
GPVI-specific CRP is relatively refractory to the inhibitory adenosine A2A receptor unless 
inhibitors of the feedback agonists ADP and TxA2 are also present.  
The observation that adenosine or the more powerful inhibitor forskolin, which induces a 
greater increase in cAMP, had no effect on clustering of GPVI, tyrosine phosphorylation of 
Syk, LAT and PLC2, elevation of Ca2+ and spreading of platelets on collagen demonstrates 
that elevation of cAMP has a minimal effect on the proximal signalling events by GPVI. This 
therefore explains why collagen in able to initiate platelet activation at sites of lesion in the 
vessel wall despite the increase in cAMP. The inhibitory effect of NECA against lower 
concentrations of collagen is therefore mediated downstream of Ca2+ signalling, including 
inhibition of the formation and action of TxA2 and secretion of ADP as shown. 
Loyau et al21 have proposed that elevation of cAMP maintains GPVI in a monomeric form as 
shown using the mAb 9E18 which recognises dimeric but not monomeric GPVI.  This suggests 
that elevation of cAMP should induce powerful inhibition of platelet activation by collagen as 
this binds selectively to the dimeric form of GPVI12. The observation that the proximal events 
in GPVI signalling are not altered by NECA or by forskolin therefore suggests the effect of 
cAMP on 9E18 binding may not be directly related to GPVI/FcR-dependent signalling. 
Takayama et al22 reported that elevation of cAMP leads to internalisation of GPVI in human 
platelets, but the lack of effect on signalling indicates that this is a relatively slow event. Taken 
together, our data suggests that the inhibitory effect of cAMP occurs downstream of GPVI 
signalling, including inhibition of the feedback agonist TxA2 and possibly via additional effects 
on integrin IIb3 activation and secretion3, 33, 34.  
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Adenosine has been previously reported to inhibit platelet activation by a number of G protein-
coupled receptor agonists including thrombin, ADP and TxA213, 14, 31, 35. In all cases, inhibition 
was mediated by loss of PLC activation in combination with elevation of cGMP and inhibition 
of IP3-induced Ca2+ release via the PKG-IRAG-IP3 receptor complex.  In our study, single cell 
Ca2+ measurements during collagen induced signalling in the presence of forskolin however 
revealed no effect on Ca2+ release signalling, questioning the significance of this mechanism. 
In conclusion, the observation that the proximal events in collagen-mediated signalling 
including Ca2+ flux are not altered by elevation of cAMP with adenosine or forskolin is 
consistent with a critical role for collagen/GPVI in mediating platelet activation at sites of 
injury to the vasculature, despite the presence of the cAMP-elevating agent, prostacyclin. 
Inhibition of platelet activation by adenosine and forskolin is overcome at higher 
concentrations of collagen which mimics the situation in the vessel wall. In addition, these 
results may have important implications for the therapeutic action of the P2Y12 inhibitor 
ticagrelor which also inhibits adenosine uptake, and this would further inhibit platelet 
signalling notably by low concentrations of collagen. Similar interactions may benefit the 
therapeutic action of the clinically-used PDE inhibitors such as cilostazol and dipyridamole. 
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Figure Captions
Fig. 1 The effect of NECA, forskolin, indomethacin (Indo) and cangrelor (Cang) on collagen 
induced platelet aggregation and ATP secretion. Platelet aggregation induced by (A, C) intermediate 
(10 μg/ml) and (B) low (2 μg/ml) concentrations of collagen was monitored by light transmission 
aggregometry at 37oC with constant stirring at 1200 rpm. Secretion of ATP was measured using 
luciferin-luciferase Chromo-lume reagent. The effect of NECA (100 μM), indomethacin (10 μM) and 
cangrelor (10 μM) on (Ai) intermediate (10 μg/ml) and (Bi) low (2 μg/ml) concentration collagen 
induced aggregation. The effect of NECA (100 μM), indomethacin (10 μM) and cangrelor (10 μM) on 
(Aii) intermediate (10 μg/ml) and (Bii) low (2 μg/ml) concentration collagen induced ATP secretion. 
Representative (Aiii) aggregation and (Aiv) secretion traces showing the effect of the inhibitors on 
intermediate concentration (10 μg/ml) collagen induced platelet aggregation and ATP secretion. 
Representative (Biii) aggregation and (Biv) secretion traces showing the effect of the inhibitors on low 
concentration (2 μg/ml) collagen induced platelet aggregation and ATP secretion. (C) The effect of 
forskolin (10 μM), indomethacin (10 μM) and cangrelor (10 μM) on intermediate (10 μg/ml) 
concentration collagen induced aggregation and ATP secretion. Representative (Ciii) aggregation and 
(Civ) secretion traces showing the effect of the inhibitors on intermediate concentration (10 μg/ml) 
collagen induced platelet aggregation and ATP secretion. Significance was measured using one-way 
ANOVA with a Bonferroni post-hoc test where, P<0.05. Data presented as mean±SEM (n=6).  
Fig. 2 The effect of NECA, indomethacin (Indo) and cangrelor (Cang) on collagen-related-peptide 
(CRP) induced platelet aggregation and ATP secretion. Platelet aggregation induced by (A) high 
(10 μg/ml) and (B) low (1 μg/ml) concentrations of CRP was monitored by light transmission 
aggregometry at 37oC with constant stirring at 1200 rpm.  Secretion of ATP was measured using 
luciferin-luciferase Chromo-lume reagent. The effect of NECA (100 μM), indomethacin (10 μM) and 
cangrelor (10 μM) on (Ai) high (10 μg/ml) and (Bi) low (1 μg/ml) concentration CRP induced 
aggregation. The effect of NECA (100 μM), indomethacin (10 μM) and cangrelor (10 μM) on (Aii) 
high (10 μg/ml) and (Bii) low (1 μg/ml) concentration CRP induced ATP secretion. Representative 
(Aiii) aggregation and (Aiv) secretion traces showing the effect of the inhibitors on high concentration 
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(10 μg/ml) CRP induced platelet aggregation and ATP secretion. Representative (Biii) aggregation and 
(Biv) secretion traces showing the effect of the inhibitors on low (1 μg/ml) concentration CRP induced 
platelet aggregation and ATP secretion. Significance was measured using one-way ANOVA with a 
Bonferroni post-hoc test where: P<0.05. Data presented as mean±SEM (n=3-6). 
Fig. 3 The effect of forskolin on collagen induced PLCγ2, Syk and LAT phosphorylation.   The 
effect of forskolin (10 μM) in the presence of maximally-effective concentrations of indomethacin (10 
μM) and apyrase (10 μM) on collagen induced (10 μg/ml) phosphorylation investigated by western 
blotting with (i) the phosphotyrosine antibody 4G10 and (ii) phosphospecific antibodies to PLCγ2, Syk 
and LAT. (iii) Quantification of band intensities where the blue line represents control and the red line 
represents phosphorylation in the presence of forskolin. Data presented as mean±SEM (n=5).
Fig. 4 NECA and forskolin have no significant effect on platelet spreading on collagen.  (A) 
Washed platelets (2x107/ml) were spread on a collagen-coated surface for 30 min at 37oC and then 
NECA (100 μM) and forskolin (10 μM) were added and platelets spread for an additional 30 min. Five 
fields of view per treatment per experiment were captured using epifluorescence microscopy and 
analysed with KMINE software (Field of view = 211 μm x 211 μm). (Ai) Representative zoomed-in 
images of platelet spreading with the indicated treatments. (Field of view= 94 μm x 94 μm) (Scale bar: 
5 μm).  Quantification of (Aii) surface area and (Aiii) platelet adhesion. (B) Washed platelets (2x107/ml) 
were pre-incubated with NECA (100 μM) and forskolin (10 μM) for 30 min followed by spreading on 
a collagen-coated surface for 30 min at 37oC. Five fields of view per treatment per experiment were 
captured using epifluorescence microscopy and analysed with KMINE software (Field of view = 211 
μm x 211 μm). (Bi) Representative zoomed-in images of platelet spreading with the indicated 
treatments. (Field of view= 94 μm x 94 μm) (Scale bar: 5 μm). Quantification of (Bii) surface area and 
(Biii) platelet adhesion. Significance was measured using one-way ANOVA with a Bonferroni post-
hoc test where: P<0.05. Data presented as mean±SEM (n=3). 
Fig. 5 Forskolin, indomethacin and cangrelor have no significant effect on collagen induced Ca2+ 
mobilisation. Washed platelets were loaded with Oregon green 488 BAPTA-1-AM and diluted to 
2x107/ml. Prior to spreading the platelets were incubated with forskolin (10 μM) or indomethacin (10 
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μM) and cangrelor (10 μM) or all three inhibitors for 2 min and then spread on a collagen-coated surface 
for 20 min at 37°C. Real-time platelet Ca2+ flux was monitored using epifluorescence microscopy for 
200 sec with images taken every 2 sec for 100 cycles. Five fields of view per treatment per experiment 
were captured and (A) the number of peaks and (B) peak fluorescence intensity were analysed in 75 
platelets for each condition. (C) Representative Ca2+ traces in a single platelet for (i) control, (ii) 
forskolin, (iii) indomethacin and cangrelor and (iv) forskolin, indomethacin and cangrelor. Data 
presented as mean±SEM (n=3).  
Fig. 6 NECA and forskolin do not change GPVI receptor clustering on collagen. Washed platelets 
(2x107/ml) were incubated with 1G5-Fab and allowed to spread on collagen for 30 min at 37oC. NECA 
(100 μM) and forskolin (10 μM) were then added to the platelet suspensions and platelets were spread 
for an additional 30 min. All STORM experiments were performed on a NIKON N-STORM 
microscope.  Seven fields of view per treatment per experiment were captured and the 20,000 frames 
captured with Nikon NIS ELEMENTS v4.5 were reconstructed in ThunderSTORM imageJ plugin. 
Cluster analysis was performed in KMINE software with an algorithm based on DBSCAN with an 
additional setting based on image dilation. (A) Representative TIRF and reconstructed STORM images 
of platelet spreading and detections with the indicated treatments. Cluster plots produced in MATLAB 
show the clusters, each represented by a different arbitrary colour. (Field of view = 40 x 40 μm) (scale 
bar: 2 μm). (B) Relative quantification of (i) number of clusters, (ii) number of detections per cluster 
and (iii) cluster area and (iv) density from seven fields of view per treatment per experiment. Data 
presented as mean±SEM (n=3).
Fig. 7 The effect of NECA and forskolin on U46619 induced platelet aggregation and the effect of 
ADP in combination with NECA on collagen induced platelet aggregation. Platelet aggregation was 
monitored by light transmission aggregometry at 37oC with constant stirring at 1200 rpm. (A) The effect 
of the inhibitors: NECA (100 μM) and forskolin (10 μM) on U46619 (3 μM) induced aggregation. (B) 
Representative aggregation traces showing the effect of the inhibitors on platelet aggregation. (C) The 
effect of NECA (100 μM) alone, ADP (10 μM) alone and in the presence of NECA on collagen induced 
aggregation. (D) Representative aggregation traces showing the effect of ADP, NECA, and both in 
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combination on platelet aggregation. Trace showing ADP alone does not cause aggregation of washed 
platelets.  Significance was measured using one-way ANOVA with a Bonferroni post-hoc test where 
P<0.05. Data presented as mean±SEM (n=3-6). 
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Fig. 1 The effect of NECA, forskolin, indomethacin (Indo) and cangrelor (Cang) on collagen induced platelet 
aggregation and ATP secretion. Platelet aggregation induced by (A, C) intermediate (10 μg/ml) and (B) low 
(2 μg/ml) concentrations of collagen was monitored by light transmission aggregometry at 37oC with 
constant stirring at 1200 rpm. Secretion of ATP was measured using luciferin-luciferase Chromo-lume 
reagent. The effect of NECA (100 μM), indomethacin (10 μM) and cangrelor (10 μM) on (Ai) intermediate 
(10 μg/ml) and (Bi) low (2 μg/ml) concentration collagen induced aggregation. The effect of NECA (100 μM), 
indomethacin (10 μM) and cangrelor (10 μM) on (Aii) intermediate (10 μg/ml) and (Bii) low (2 μg/ml) 
concentration collagen induced ATP secretion. Representative (Aiii) aggregation and (Aiv) secretion traces 
showing the effect of the inhibitors on intermediate concentration (10 μg/ml) collagen induced platelet 
aggregation and ATP secretion. Representative (Biii) aggregation and (Biv) secretion traces showing the 
effect of the inhibitors on low concentration (2 μg/ml) collagen induced platelet aggregation and ATP 
secretion. (C) The effect of forskolin (10 μM), indomethacin (10 μM) and cangrelor (10 μM) on intermediate 
(10 μg/ml) concentration collagen induced aggregation and ATP secretion. Representative (Ciii) aggregation 
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and (Civ) secretion traces showing the effect of the inhibitors on intermediate concentration (10 μg/ml) 
collagen induced platelet aggregation and ATP secretion. Significance was measured using one-way ANOVA 
with a Bonferroni post-hoc test where, P<0.05. Data presented as mean±SEM (n=6).   
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Fig. 2 The effect of NECA, indomethacin (Indo) and cangrelor (Cang) on collagen-related-peptide (CRP) 
induced platelet aggregation and ATP secretion. Platelet aggregation induced by (A) high (10 μg/ml) and (B) 
low (1 μg/ml) concentrations of CRP was monitored by light transmission aggregometry at 37oC with 
constant stirring at 1200 rpm.  Secretion of ATP was measured using luciferin-luciferase Chromo-lume 
reagent. The effect of NECA (100 μM), indomethacin (10 μM) and cangrelor (10 μM) on (Ai) high (10 μg/ml) 
and (Bi) low (1 μg/ml) concentration CRP induced aggregation. The effect of NECA (100 μM), indomethacin 
(10 μM) and cangrelor (10 μM) on (Aii) high (10 μg/ml) and (Bii) low (1 μg/ml) concentration CRP induced 
ATP secretion. Representative (Aiii) aggregation and (Aiv) secretion traces showing the effect of the 
inhibitors on high concentration (10 μg/ml) CRP induced platelet aggregation and ATP secretion. 
Representative (Biii) aggregation and (Biv) secretion traces showing the effect of the inhibitors on low (1 
μg/ml) concentration CRP induced platelet aggregation and ATP secretion. Significance was measured using 
one-way ANOVA with a Bonferroni post-hoc test where: P<0.05. Data presented as mean±SEM (n=3-6). 
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Fig. 3 The effect of forskolin on collagen induced PLCγ2, Syk and LAT phosphorylation.   The effect of 
forskolin (10 μM) in the presence of maximally-effective concentrations of indomethacin (10 μM) and 
apyrase (10 μM) on collagen induced (10 μg/ml) phosphorylation investigated by western blotting with (i) 
the phosphotyrosine antibody 4G10 and (ii) phosphospecific antibodies to PLCγ2, Syk and LAT. (iii) 
Quantification of band intensities where the blue line represents control and the red line represents 
phosphorylation in the presence of forskolin. Data presented as mean±SEM (n=5). 
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Fig. 4 NECA and forskolin have no significant effect on platelet spreading on collagen.  (A) Washed platelets 
(2x107/ml) were spread on a collagen-coated surface for 30 min at 37oC and then NECA (100 μM) and 
forskolin (10 μM) were added and platelets spread for an additional 30 min. Five fields of view per treatment 
per experiment were captured using epifluorescence microscopy and analysed with KMINE software (Field of 
view = 211 μm x 211 μm). (Ai) Representative zoomed-in images of platelet spreading with the indicated 
treatments. (Field of view= 94 μm x 94 μm) (Scale bar: 5 μm).  Quantification of (Aii) surface area and 
(Aiii) platelet adhesion. (B) Washed platelets (2x107/ml) were pre-incubated with NECA (100 μM) and 
forskolin (10 μM) for 30 min followed by spreading on a collagen-coated surface for 30 min at 37oC. Five 
fields of view per treatment per experiment were captured using epifluorescence microscopy and analysed 
with KMINE software (Field of view = 211 μm x 211 μm). (Bi) Representative zoomed-in images of platelet 
spreading with the indicated treatments. (Field of view= 94 μm x 94 μm) (Scale bar: 5 μm). Quantification 
of (Bii) surface area and (Biii) platelet adhesion. Significance was measured using one-way ANOVA with a 
Bonferroni post-hoc test where: P<0.05. Data presented as mean±SEM (n=3). 
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Fig. 5 Forskolin, indomethacin and cangrelor have no significant effect on collagen induced Ca2+ 
mobilisation. Washed platelets were loaded with Oregon green 488 BAPTA-1-AM and diluted to 2x107/ml. 
Prior to spreading the platelets were incubated with forskolin (10 μM) or indomethacin (10 μM) and 
cangrelor (10 μM) or all three inhibitors for 2 min and then spread on a collagen-coated surface for 20 min 
at 37°C. Real-time platelet Ca2+ flux was monitored using epifluorescence microscopy for 200 sec with 
images taken every 2 sec for 100 cycles. Five fields of view per treatment per experiment were captured 
and (A) the number of peaks and (B) peak fluorescence intensity were analysed in 75 platelets for each 
condition. (C) Representative Ca2+ traces in a single platelet for (i) control, (ii) forskolin, (iii) indomethacin 
and cangrelor and (iv) forskolin, indomethacin and cangrelor. Data presented as mean±SEM (n=3).   
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Fig. 6 NECA and forskolin do not change GPVI receptor clustering on collagen. Washed platelets (2x107/ml) 
were incubated with 1G5-Fab and allowed to spread on collagen for 30 min at 37oC. NECA (100 μM) and 
forskolin (10 μM) were then added to the platelet suspensions and platelets were spread for an additional 30 
min. All STORM experiments were performed on a NIKON N-STORM microscope.  Seven fields of view per 
treatment per experiment were captured and the 20,000 frames captured with Nikon NIS ELEMENTS v4.5 
were reconstructed in ThunderSTORM imageJ plugin. Cluster analysis was performed in KMINE software with 
an algorithm based on DBSCAN with an additional setting based on image dilation. (A) Representative TIRF 
and reconstructed STORM images of platelet spreading and detections with the indicated treatments. Cluster 
plots produced in MATLAB show the clusters, each represented by a different arbitrary colour. (Field of view 
= 40 x 40 μm) (scale bar: 2 μm). (B) Relative quantification of (i) number of clusters, (ii) number of 
detections per cluster and (iii) cluster area and (iv) density from seven fields of view per treatment per 
experiment. Data presented as mean±SEM (n=3). 
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Fig. 7 The effect of NECA and forskolin on U46619 induced platelet aggregation and the effect of ADP in 
combination with NECA on collagen induced platelet aggregation. Platelet aggregation was monitored by 
light transmission aggregometry at 37oC with constant stirring at 1200 rpm. (A) The effect of the inhibitors: 
NECA (100 μM) and forskolin (10 μM) on U46619 (3 μM) induced aggregation. (B) Representative 
aggregation traces showing the effect of the inhibitors on platelet aggregation. (C) The effect of NECA (100 
μM) alone, ADP (10 μM) alone and in the presence of NECA on collagen induced aggregation. (D) 
Representative aggregation traces showing the effect of ADP, NECA, and both in combination on platelet 
aggregation. Trace showing ADP alone does not cause aggregation of washed platelets.  Significance was 
measured using one-way ANOVA with a Bonferroni post-hoc test where P<0.05. Data presented as 
mean±SEM (n=3-6). 
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